Streamlining GLP-1 prior Authorizations: A New Era of Efficiency The prior authorization (PA) process for glucagon-like peptide-1 (GLP-1) medications has long been a source of frustration for both health care providers and patients. The administrative burden, potential for errors, and resulting delays in treatment initiation can significantly impact patient outcomes. Tho, advancements in electronic prior … Read more
You can read the full story here: Electronic Prior Authorization: Tech’s Latest Innovations .